Laurel Wealth Advisors (North Carolina)’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $757K | Buy |
29,069
+28,312
| +3,740% | +$737K | 0.01% | 290 |
|
|
2025
Q1 | $29.3K | Hold |
757
| – | – | ﹤0.01% | 368 |
|
|
2024
Q4 | $25.6K | Sell |
757
-30
| -4% | -$1.02K | ﹤0.01% | 389 |
|
|
2024
Q3 | $32.2K | Buy |
787
+423
| +116% | +$17.3K | 0.01% | 358 |
|
|
2024
Q2 | $14K | Hold |
364
| – | – | ﹤0.01% | 404 |
|
|
2024
Q1 | $15.6K | Hold |
364
| – | – | ﹤0.01% | 399 |
|
|
2023
Q4 | $13.5K | Hold |
364
| – | – | ﹤0.01% | 379 |
|
|
2023
Q3 | $13.2K | Hold |
364
| – | – | ﹤0.01% | 380 |
|
|
2023
Q2 | $13K | Hold |
364
| – | – | ﹤0.01% | 391 |
|
|
2023
Q1 | $13K | Hold |
364
| – | – | ﹤0.01% | 391 |
|
|
2022
Q4 | $12.8K | Hold |
364
| – | – | ﹤0.01% | 368 |
|
|
2022
Q3 | $11K | Buy |
+364
| New | +$11K | ﹤0.01% | 376 |
|
|
2022
Q2 | – | Sell |
-364
| Closed | -$20K | – | 654 |
|
|
2022
Q1 | $20K | Hold |
364
| – | – | ﹤0.01% | 342 |
|
|
2021
Q4 | $20K | Hold |
364
| – | – | ﹤0.01% | 342 |
|
|
2021
Q3 | $17K | Hold |
364
| – | – | ﹤0.01% | 356 |
|
|
2021
Q2 | $18K | Hold |
364
| – | – | ﹤0.01% | 387 |
|
|
2021
Q1 | $16K | Hold |
364
| – | – | ﹤0.01% | 372 |
|
|
2020
Q4 | $17K | Sell |
364
-400
| -52% | -$18.7K | ﹤0.01% | 362 |
|
|
2020
Q3 | $36K | Hold |
764
| – | – | 0.01% | 268 |
|
|
2020
Q2 | $39K | Buy |
764
+400
| +110% | +$20.4K | 0.01% | 251 |
|
|
2020
Q1 | $17K | Hold |
364
| – | – | 0.01% | 305 |
|
|
2019
Q4 | $21K | Hold |
364
| – | – | 0.01% | 319 |
|
|
2019
Q3 | $19K | Hold |
364
| – | – | 0.01% | 320 |
|
|
2019
Q2 | $18K | Hold |
364
| – | – | 0.01% | 328 |
|
|
2019
Q1 | $19K | Hold |
364
| – | – | 0.01% | 312 |
|
|
2018
Q4 | $17K | Buy |
+364
| New | +$17K | 0.01% | 305 |
|